site logo

Merck joins peers in spinning off lower growth drugs

The company expects to receive up to $9 billion through a tax-free dividend and more than $1.5 billion in efficiencies by spinning out women's health and legacy drugs into a new company.

Jacob Bell / BioPharma Dive